Severity of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in African Americans

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2014 Sep 3

PMID 25181310

Citations 14

Authors

Isabel Blanco

Stephen Mathai

Majid Shafiq

Danielle Boyce

Todd M Kolb

Hala Chami

Laura K Hummers

Traci Housten

Neal Chaisson

Ari L Zaiman

Fredrick M Wigley

Ryan J Tedford

David A Kass

Rachel Damico

Reda E Girgis

Paul M Hassoun

Affiliations

Soon will be listed here.

Abstract

African Americans (AA) with systemic sclerosis (SSc) have a worse prognosis compared to Americans of European descent (EA). We conducted the current study to test the hypothesis that AA patients with SSc have more severe disease and poorer outcomes compared to EA patients when afflicted with pulmonary arterial hypertension (PAH). We studied 160 consecutive SSc patients with PAH diagnosed by right heart catheterization, comparing demographics, hemodynamics, and outcomes between AA and EA patients. The cohort included 29 AA and 131 EA patients with similar baseline characteristics except for increased prevalence of diffuse SSc in AA. AA patients had worse functional class (FC) (80% FC III-IV vs 53%; p = 0.02), higher brain natriuretic peptide (NT-pro-BNP) (5729 ± 9730 pg/mL vs 1892 ± 2417 pg/mL; p = 0.02), more depressed right ventricular function, a trend toward lower 6-minute walk distance (263 ± 111 m vs 333 ± 110 m; p = 0.07), and worse hemodynamics (cardiac index 1.95 ± 0.58 L/min/m vs 2.62 ± 0.80 L/min/m; pulmonary vascular resistance 10.3 ± 6.2 WU vs 7.6 ± 5.0 WU; p < 0.05) compared with EA patients. Kaplan-Meier survival estimates for AA and EA patients, respectively, were 62% vs 73% at 2 years and 26% vs 44% at 5 years (p > 0.05). In conclusion, AA patients with SSc-PAH are more likely to have diffuse SSc and to present with significantly more severe PAH compared with EA patients. AA patients also appear to have poorer survival, though larger studies are needed to investigate this association definitively.

Citing Articles

EVALUATION OF PATIENTS WITH COVID-19 IN THE EARLY HYPOXEMIC STAGE AND PATIENTS WITH VIRAL RESPIRATORY TRACT INFECTION IN TERMS OF PULMONARY HYPERTENSION.

Cinaroglu S, Karakus K, Keles H, Kacmaz M Acta Clin Croat. 2024; 62(3):478-485.

PMID: 39310698 PMC: 11414004. DOI: 10.20471/acc.2023.62.03.10.

Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review.

Contreras J, Nussbaum J, Cangialosi P, Thapi S, Radakrishnan A, Hall J J Clin Med. 2024; 13(1).

PMID: 38202292 PMC: 10779488. DOI: 10.3390/jcm13010285.

Health Care Disparities in Pulmonary Arterial Hypertension.

Bernardo R, de Jesus Perez V Clin Chest Med. 2023; 44(3):543-554.

PMID: 37517834 PMC: 10715710. DOI: 10.1016/j.ccm.2023.03.010.

Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.

Vilela V, Dias M, Salgado A, da Silva B, Lopes A, Bessa E BMC Pulm Med. 2021; 21(1):251.

PMID: 34325685 PMC: 8323291. DOI: 10.1186/s12890-021-01618-z.

Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.

Showalter K, Pinheiro L, Jannat-Khah D, Sobol I, Szymonifka J, Finik J Rheumatology (Oxford). 2021; 61(4):1510-1517.

PMID: 34273167 PMC: 9216039. DOI: 10.1093/rheumatology/keab569.

References

Cole R, Kalogeropoulos A, Georgiopoulou V, Gheorghiade M, Quyyumi A, Yancy C . Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011; 123(21):2414-22. DOI: 10.1161/CIRCULATIONAHA.110.012781. View

Chung L, Liu J, Parsons L, Hassoun P, McGoon M, Badesch D . Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010; 138(6):1383-94. PMC: 3621419. DOI: 10.1378/chest.10-0260. View

Mayes M, Lacey Jr J, Beebe-Dimmer J, Gillespie B, Cooper B, Laing T . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48(8):2246-55. DOI: 10.1002/art.11073. View

Campo A, Mathai S, Le Pavec J, Zaiman A, Hummers L, Boyce D . Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 182(2):252-60. PMC: 2913238. DOI: 10.1164/rccm.200912-1820OC. View

Villalba W, Sampaio-Barros P, Pereira M, Cerqueira E, Leme Jr C, Marques-Neto J . Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest. 2007; 131(1):217-22. DOI: 10.1378/chest.06-0630. View

Gabler N, French B, Strom B, Liu Z, Palevsky H, Taichman D . Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2011; 141(1):20-26. PMC: 5991545. DOI: 10.1378/chest.11-0404. View

Hummer R, Chinn J . RACE/ETHNICITY AND U.S. ADULT MORTALITY: Progress, Prospects, and New Analyses. Du Bois Rev. 2011; 8(1):5-24. PMC: 3116787. DOI: 10.1017/S1742058X11000051. View

Fisher M, Mathai S, Champion H, Girgis R, Housten-Harris T, Hummers L . Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006; 54(9):3043-50. DOI: 10.1002/art.22069. View

Fields L, Burt V, Cutler J, Hughes J, Roccella E, Sorlie P . The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004; 44(4):398-404. DOI: 10.1161/01.HYP.0000142248.54761.56. View

10.

Benza R, Miller D, Gomberg-Maitland M, Frantz R, Foreman A, Coffey C . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164-72. DOI: 10.1161/CIRCULATIONAHA.109.898122. View

11.

Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102(8):865-70. DOI: 10.1161/01.cir.102.8.865. View

12.

Leuchte H, Holzapfel M, Baumgartner R, Ding I, Neurohr C, Vogeser M . Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004; 43(5):764-70. DOI: 10.1016/j.jacc.2003.09.051. View

13.

Kawut S, Horn E, Berekashvili K, Garofano R, Goldsmith R, Widlitz A . New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005; 95(2):199-203. DOI: 10.1016/j.amjcard.2004.09.006. View

14.

Badesch D, Champion H, Gomez Sanchez M, Hoeper M, Loyd J, Manes A . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S55-S66. DOI: 10.1016/j.jacc.2009.04.011. View

15.

Reveille J . Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003; 5(2):160-7. DOI: 10.1007/s11926-003-0045-1. View

16.

Reveille J, Fischbach M, McNearney T, Friedman A, Aguilar M, Lisse J . Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001; 30(5):332-46. DOI: 10.1053/sarh.2001.20268. View

17.

Schoindre Y, Meune C, Dinh-Xuan A, Avouac J, Kahan A, Allanore Y . Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol. 2009; 36(7):1481-5. DOI: 10.3899/jrheum.081221. View

18.

Fisher M, Forfia P, Chamera E, Housten-Harris T, Champion H, Girgis R . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(7):615-21. PMC: 2720125. DOI: 10.1164/rccm.200811-1691OC. View

19.

Hinchcliff M, Desai C, Varga J, Shah S . Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol. 2012; 30(2 Suppl 71):S30-7. PMC: 3507505. View

20.

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View